Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

@article{Vincken2002ImprovedHO,
  title={Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium},
  author={Walter Vincken and Jan A van Noord and A. P. M. Greefhorst and Theo A Bantje and Steven Kesten and Lawrence Korducki and P. J. G. Cornelissen},
  journal={European Respiratory Journal},
  year={2002},
  volume={19},
  pages={209 - 216}
}
Tiotropium, a novel once-daily inhaled anticholinergic, has been shown to improve lung function over a 24-h period. In order to extend these findings, health-outcomes were evaluated over 1 yr in chronic obstructive pulmonary disease (COPD) patients. Spirometric results, peak expiratory flow rate (PEFR), salbutamol use and effects on dyspnoea, health-related quality of life and COPD exacerbations were assessed in two identical 1-yr randomized double-blind double-dummy studies of tiotropium 18µg… Expand
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
TLDR
Tiotropium is an effective, once-daily bronchodilator that reduces dyspnoea and chronic obstructive pulmonary disease exacerbation frequency and improves health status and that will make an important contribution to chronic obstructives pulmonary disease therapy. Expand
A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
TLDR
Therapy with tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV(1). Expand
A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease.
TLDR
Compared with the placebo group, tiotropium provides sustained improvements in lung function in patients with COPD, with improvements for smokers and ex-smokers. Expand
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
The aim of this paper is to assess the health economic consequences of substituting ipratropium with the new, once-daily bronchodilator tiotropium in patients with a diagnosis of chronic obstructiveExpand
One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium.
TLDR
Based on a retrospective analysis of 1-year, placebo-controlled clinical trials, tiotropium was associated with a reduced rate of loss of FEV1, and long-term trials specifically designed to study this effect are required. Expand
The effect of tiotropium on exacerbations and airflow in patients with COPD
TLDR
Tiotropium reduced exacerbations and associated health resource use, and improved airflow over 1 yr in chronic obstructive pulmonary disease patients. Expand
Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
TLDR
Tiotropium demonstrated significantly greater post-dose improvements in spirometric parameters compared with salmeterol and these improvements were sustained over 12 h. Expand
Evaluation of withdrawal of maintenance tiotropium in COPD.
TLDR
The withdrawal of tiotropium results in worsening of COPD over a three-week interval, and there was no evidence of a rebound effect in response to tiottropium withdrawal. Expand
Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses.
TLDR
Tiotropium was effective in the treatment of patients with COPD, irrespective of the presence or absence of a short-term response on the first day of treatment, and should not be used as a definitive criterion for prescribing long-term treatment with inhaled bronchodilators. Expand
The effect of tiotropium on exacerbations and airflow in patients with COPD.
TLDR
Tiotropium significantly improved trough (pre-dose) FEV1, forced vital capacity, slow vital capacity and inspiratory capacity versus placebo, and improved airflow over 1 yr in chronic obstructive pulmonary disease patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease
TLDR
Tiotropium in a dose of 18 μg inhaled once daily using the HandiHaler was significantly more effective than 40”μg ipratropium four times daily in improving trough, average, and peak lung function over the 13 week period. Expand
Quality of life changes in COPD patients treated with salmeterol.
  • P. Jones, T. Bosh
  • Medicine
  • American journal of respiratory and critical care medicine
  • 1997
TLDR
It is shown that a modest change in lung function may be associated with clinically significant gain in health and well-being in COPD patients. Expand
Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.
TLDR
Of the available parameters, increased IC, which is an index of reduced resting lung hyperinflation, best reflected the improvements in exercise endurance and dyspnea after IB. Expand
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
TLDR
It is suggested that patient quality of life is related to COPD exacerbation frequency and factors predictive of frequent exacerbations were daily cough, daily wheeze, and daily cough and sputum. Expand
Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
TLDR
In this population of patients with COPD, tiotropium bromide was found to be a safe and long-acting bronchodilator, demonstrating a clear dose-response relationship following single dose administration. Expand
Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease.
TLDR
Improvements in spirometry with once-daily dosing confirm the long duration of action of tiotropium reported in single-dose studies, and its sustained improvement of spirometric measures over the 1 mo of testing in the study points to utility of t Elliotropium as a maintenance bronchodilator for patients with COPD. Expand
Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD.
TLDR
Ipratropium and metaproterenol similarly improved pulmonary function in COPD patients when stable and during acute exacerbations. Expand
Efficacy of salmeterol xinafoate in the treatment of COPD.
TLDR
These collective data support the use of salmeterol as first-line bronchodilator therapy for the long-term treatment of airflow obstruction in patients with COPD. Expand
Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease
TLDR
Salmeterol provided similar maximal bronchodilatation to ipratropium but had a longer duration of action and a more constant bronchidilatory effect with no evidence of bronchODilator tolerance. Expand
Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease.
TLDR
In patients with COPD, inhaled bronchodilator reduces exercise DH and improves inspiratory pressure reserve and neuroventilatory coupling, which are the main determinants of reduced breathlessness. Expand
...
1
2
3
4
...